Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | SVP, External Affairs | December 11, 2020 | December 11, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date December 11, 2020 · Filed December 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-12-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-12-11 · Exercise / conversion · Acquired 50,000 · Balance 50,000 Row 2 · 2020-12-11 · Sale · Disposed 50,000 · Balance 0 F1: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.98 to 56.60, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.55 · Expires 2028-02-07 | Direct | 155,000 |
Reported balance
After 2020-12-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-11 · Exercise / conversion · Disposed 50,000 · Balance 155,000 F2: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.98 to 56.60, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F2: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2020 Filed Dec 11, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-063102 · doc4.xml · derivative · entry 3 SANG CHARLES · CIK 0001780656 · SVP, External Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 50,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 11, 2020 Filed Dec 11, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 50,000 | $56.13 | $2,806,500.00 |
DisclosureSEC source: 0001209191-20-063102 · doc4.xml · nonDerivative · entry 2 SANG CHARLES · CIK 0001780656 · SVP, External Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.98 to 56.60, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 11, 2020 Filed Dec 11, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 50,000 | $6.55 | $327,500.00 |
DisclosureSEC source: 0001209191-20-063102 · doc4.xml · nonDerivative · entry 1 SANG CHARLES · CIK 0001780656 · SVP, External Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-050780 · doc4.xml · derivative · entry 6 SANG CHARLES · CIK 0001780656 · SVP, External Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 25,000 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 25,000 | $44.00 | $1,100,000.00 |
DisclosureSEC source: 0001209191-20-050780 · doc4.xml · nonDerivative · entry 4 SANG CHARLES · CIK 0001780656 · SVP, External Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 25,000 | $6.32 | $158,000.00 |
DisclosureSEC source: 0001209191-20-050780 · doc4.xml · nonDerivative · entry 3 SANG CHARLES · CIK 0001780656 · SVP, External Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-050780 · doc4.xml · derivative · entry 5 SANG CHARLES · CIK 0001780656 · SVP, External Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 25,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 25,000 | $42.50 | $1,062,500.00 |
DisclosureSEC source: 0001209191-20-050780 · doc4.xml · nonDerivative · entry 2 SANG CHARLES · CIK 0001780656 · SVP, External Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $42.50 to 42.51, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 25,000 | $6.55 | $163,750.00 |
DisclosureSEC source: 0001209191-20-050780 · doc4.xml · nonDerivative · entry 1 SANG CHARLES · CIK 0001780656 · SVP, External Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 18, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-030299 · doc4.xml · derivative · entry 5 SANG CHARLES · CIK 0001780656 · SVP, Clinical Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 20,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| May 15, 2020 Filed May 18, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-030299 · doc4.xml · derivative · entry 4 SANG CHARLES · CIK 0001780656 · SVP, Clinical Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 20,000 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 15, 2020 Filed May 18, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 40,000 | $38.01 | $1,520,400.00 |
DisclosureSEC source: 0001209191-20-030299 · doc4.xml · nonDerivative · entry 3 SANG CHARLES · CIK 0001780656 · SVP, Clinical Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.78 to 38.25, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| May 15, 2020 Filed May 18, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 20,000 | $6.55 | $131,000.00 |
DisclosureSEC source: 0001209191-20-030299 · doc4.xml · nonDerivative · entry 2 SANG CHARLES · CIK 0001780656 · SVP, Clinical Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 18, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 20,000 | $6.32 | $126,400.00 |
DisclosureSEC source: 0001209191-20-030299 · doc4.xml · nonDerivative · entry 1 SANG CHARLES · CIK 0001780656 · SVP, Clinical Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 07:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009863 · doc4.xml · derivative · entry 1 SANG CHARLES · CIK 0001780656 · SVP, Clinical Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.